Navigation Links
Angiotech wins before the UK House of Lords
Date:7/10/2008

VANCOUVER, July 10 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, announced that yesterday, the highest court of the United Kingdom, the House of Lords, confirmed in a precedent-setting decision the validity of one of Angiotech's patents related to its paclitaxel stent inventions. As Lord Neuberger of Abbotsbury, commented, "The decision represents a significant development in the United Kingdom patent law".

"We are pleased that the House of Lords entered final judgment in Angiotech's favor and view this outcome as further proof of the continued strength of our paclitaxel stent patent portfolio throughout the world," said Dr. Bill Hunter, President and CEO of Angiotech. "We remain committed to vigorously protecting our proprietary technologies and defending our intellectual property, and reaching supportive conclusion on this decision reaffirms this commitment," added Dr. Hunter.

The patent at issue was granted to Angiotech Pharmaceuticals Inc. by the European Patent Office (the "EPO") on June 25, 1997. At the EPO, five different companies opposed the patent. After over nine years of legal battles their challenge proved unsuccessful and the validity of the patent was maintained. On February 1, 2005, Angiotech commenced suit against Conor Medsystems Inc. ("Conor") in the Netherlands. Conor responded by commencing proceedings in the UK to revoke the patent. Conor argued that, as of July 1993 (the priority date), the claims in the patent lacked inventive step (i.e., were obvious) under UK law.

Both the UK trial court and the UK Court of Appeal decided that the patent was invalid in view of several publications. Within the sa
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Highlights Trends In eCTD Migration And Submissions Outsourcing And, Provides ... ... America And Europe, PHILADELPHIA and LONDON, July 17 ... its 2008,Liquent Regulatory Affairs Trends Survey. The survey attracted respondents,from across ...
... Johnson & Johnson Pharmaceutical,Research & Development, L.L.C. ... (FDA) Anti-Infective Drugs Advisory Committee voted in,favor of ... for,injection) for the treatment of hospital-acquired pneumonia, or ... committee voted that 500 mg of DORIBAX at ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today ... Sankyo), has received marketing,approval from the Japanese Ministry ... extension of Biopten(R) (sapropterin dihydrochloride), which,contains the same ... the,treatment of patients with phenylketonuria (PKU). BioMarin will ...
Cached Biology Technology:The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 2The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results 3FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia 2FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia 3FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia 4Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 2Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 3Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU 4
(Date:7/9/2014)... are turning to more healthful alternatives to their savored ... mean low satisfaction. Now researchers are reporting new progress ... are made with olive oil rather than pork fat. ... Agricultural and Food Chemistry . , Ana M. Herrero ... expect just the right amount of chewiness and springiness, ...
(Date:7/9/2014)... census of Adlie penguins shows that the population ... larger than previously estimated. Adlie penguins have long ... and understand the effects of climate change and ... high-resolution satellite imagery, researchers from Stony Brook University ... method that permits regular monitoring of Adlie penguins ...
(Date:7/9/2014)... economy driven by methane, the primary component of natural gas, ... boom. It has poised the country as a top fuel ... just how climate-friendly it is, according to an article in ... magazine of the American Chemical Society. , In the article, ... burned as a fuel to produce electricity, methane emits about ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... (FDA) today approved Symlin, an injectable medicine to control blood ... Symlin is to be used in addition to insulin therapy ... sugars on intensive insulin therapy alone. , Symlin will be ... other than insulin. Patients with type 2 diabetes already have ...
... of Liverpool have discovered how fish have evolved over ... different water depths. , A research team led by ... of Biological Sciences, has revealed how modern fish, such ... floating at certain water levels using a gas-filled swimbladder. ...
... Genomed-Health 2005 workshop in Tunisia, supported by the ... sciences in improving health in countries bordering the ... the importance of Euro-Mediterranean partnerships in order to ... ?in particular following the mapping of the human ...
Cached Biology News:FDA Approves New Drug to Treat Type I and Type II Diabetes 2Scientists discover how fish evolved to float at different sea depths 2Measuring the impact of post-genomics on Mediterranean populations 2
... fromStreptomyces griseolusthat inhibits protein synthesis. Acts ... eukaryote ribosomes. Reported to induce apoptosis ... promyelocytic leukemia cells, Jurkat cells, ventricular ... intracellular signals and immediate early gene ...
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... Eclipse is a state-of-the-art separation system using ... technique. The Eclipse integrates easily with Wyatts ... Tristar, as well as the Optilab DSP. ... molar mass distributions of the particles/molecules separated ...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: